CoChat

Mechanisms involved in follistatin‐induced hypertrophy and increased insulin action in skeletal muscle

Open access
Han, Xiuqing, Møller, Lisbeth Liliendal Valbjørn, De Groote, Estelle, Bojsen‐Møller, Kirstine Nyvold, Davey, Jonathan, Henríquez‐Olguin, Carlos, Li, Zhencheng, Knudsen, Jonas Roland, Jensen, Thomas Elbenhardt, Madsbad, Sten, Gregorevic, Paul, Richter, Erik Arne, Sylow, Lykke · 2019 · Journal of Cachexia, Sarcopenia and Muscle

Published version of a preprint

Cited by 75

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Background: Skeletal muscle wasting is often associated with insulin resistance. A major regulator of muscle mass is the transforming growth factor β (TGF‐β) superfamily, including activin A, which causes atrophy. TGF‐β superfamily ligands also negatively regulate insulin‐sensitive proteins, but whether this pathway contributes to insulin action remains to be determined. Methods: To elucidate if TGF‐β superfamily ligands regulate insulin action, we used an adeno‐associated virus gene editing approach to overexpress an activin A inhibitor, follistatin (Fst288), in mouse muscle of lean and diet‐induced obese mice. We determined basal and insulin‐stimulated 2‐deoxy‐glucose uptake using isotopic tracers in vivo . Furthermore, to evaluate whether circulating Fst and activin A concentrations are associated with obesity, insulin resistance, and weight loss in humans, we analysed serum from morbidly obese subjects before, 1 week, and 1 year after Roux‐en‐Y gastric bypass (RYGB). Results: Fst288 muscle overexpression markedly increased in vivo insulin‐stimulated (but not basal) glucose uptake (+75%, P < 0.05) and increased protein expression and intracellular insulin signalling of AKT, TBC1D4, PAK1, pyruvate dehydrogenase‐E1α, and p70S6K, while decreasing TBC1D1 signaling ( P < 0.05). Fst288 increased both basal and insulin‐stimulated protein synthesis, but no correlation was observed between the Fst288‐driven hypertrophy and the increase in insulin‐stimulated glucose uptake. Importantly, Fst288 completely normalized muscle glucose uptake in insulin‐resistant diet‐induced obese mice. RYGB surgery doubled circulating Fst and reduced activin A (−24%, P < 0.05) concentration 1 week after surgery before any significant weight loss in morbidly obese normoglycemic patients, while major weight loss after 1 year did not further change the concentrations. Conclusions: We here present evidence that Fst is a potent regulator of insulin action in muscle, and in addition to AKT and p70S6K, we identify TBC1D1, TBC1D4, pyruvate dehydrogenase‐E1α, and PAK1 as Fst targets. Circulating Fst more than doubled post‐RYGB surgery, a treatment that markedly improved insulin sensitivity, suggesting a role for Fst in regulating glycaemic control. These findings demonstrate the therapeutic potential of inhibiting TGF‐β superfamily ligands to improve insulin action and Fst's relevance to muscle wasting‐associated insulin‐resistant conditions in mice and humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/jcsm.12474

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 50

  1. 10.1016/S0140-6736(14)62000-6 · DOI · Paper page
  2. 10.1093/annonc/mdx815 · DOI · Paper page
  3. 10.1038/521430a · DOI
  4. 10.1530/JOE-15-0533 · DOI · Paper page
  5. 10.1096/fj.05-4607fje · DOI · Paper page
  6. 10.2337/db07-0887 · DOI · Paper page
  7. 10.1096/fj.07-8673com · DOI · Paper page
  8. 10.1126/scitranslmed.3000112 · DOI · Paper page
  9. 10.1124/jpet.113.211169 · DOI
  10. 10.1038/srep17535 · DOI
  11. 10.1016/j.ymthe.2017.02.015 · DOI · Paper page
  12. 10.1016/j.cellsig.2013.11.007 · DOI
  13. 10.2337/db06-0823 · DOI · Paper page
  14. 10.2337/db12-1148 · DOI · Paper page
  15. 10.1016/j.ymthe.2004.07.016 · DOI · Paper page
  16. 10.1042/bj2280103 · DOI · Paper page
  17. 10.1074/jbc.M408312200 · DOI · Paper page
  18. 10.1113/JP275602 · DOI · Paper page
  19. 10.1016/0003-2697(67)90167-4 · DOI · Paper page
  20. 10.2337/db13-1307 · DOI · Paper page
  21. 10.2337/db06-0152 · DOI · Paper page
  22. 10.1152/ajpregu.00400.2010 · DOI
  23. 10.1126/science.1106148 · DOI · Paper page
  24. 10.1007/s00125-014-3395-5 · DOI · Paper page
  25. 10.1042/BJ20071114 · DOI · Paper page
  26. 10.1021/acs.jproteome.7b00069 · DOI
  27. 10.1113/jphysiol.2004.076158 · DOI · Paper page
  28. 10.1152/ajpendo.00526.2002 · DOI · Paper page
  29. RocheTE BakerJC YanX HiromasaY GongX PengTet al.Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms.2001. pp.33–75. · DOI · Paper page
  30. 10.1038/emm.2001.32 · DOI · Paper page
  31. 10.1038/nrendo.2017.161 · DOI · Paper page
  32. 10.2337/diabetes.53.suppl_3.S215 · DOI · Paper page
  33. 10.1111/j.1464-5491.1992.tb01813.x · DOI · Paper page
  34. 10.1007/s00335-014-9533-z · DOI · Paper page
  35. 10.1152/ajpregu.00228.2014 · DOI · Paper page
  36. 10.2147/DMSO.S159315 · DOI
  37. 10.1016/S1357-2725(98)00064-8 · DOI
  38. 10.1530/REP-07-0208 · DOI
  39. 10.1210/jc.2011-1665 · DOI · Paper page
  40. 10.1074/jbc.270.50.29928 · DOI · Paper page
  41. 10.1210/en.2011-1687 · DOI
  42. 10.1093/ajcn/82.2.355 · doi:10.1093/ajcn/82.2.355
  43. 10.1016/j.cmet.2013.03.015 · DOI · Paper page
  44. 10.1042/BST20170479 · DOI · Paper page
  45. 10.1210/en.2012-2147 · DOI · Paper page
  46. 10.1002/jbmr.2285 · DOI · Paper page
  47. 10.1016/j.bbrc.2013.10.005 · DOI
  48. 10.2337/db11-1572 · DOI · Paper page
  49. 10.1038/mt.2014.200 · DOI · Paper page
  50. 10.1002/jcsm.12261 · DOI · Paper page

Cited by

See all 75

Metadata

Authors
Han, X., Møller, L. L. V., De Groote, E., Bojsen‐Møller, K. N., Davey, J., Henríquez‐Olguin, C., Li, Z., Knudsen, J. R., Jensen, T. E., Madsbad, S., Gregorevic, P., Richter, E. A., & Sylow, L.
Venue
Journal of Cachexia, Sarcopenia and Muscle
Publisher
Wiley
Published
2019-08-11
Volume
10
Issue
6
Pages
1241-1257
ISSN
  • 2190-5991 (ISSN-L)
  • 2190-6009
OpenAlex
W2967247987
Cited by
75
References
27
FWCI
2.43
Type
journal article
Language
en
Open access
gold
Funders
  • Comisión Nacional de Investigación Científica y Tecnológica
  • China Scholarship Council
  • Novo Nordisk Fonden (#32082, #15182)
  • Natur og Univers, Det Frie Forskningsråd (DFF‐6108‐00203A, DFF‐4004‐00233)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms involved in follistatin‐induced hypertrophy and increased insulin action in skeletal muscle. https://app.cochat.ai/papers/10.1002/jcsm.12474
The paper
Han, X., Møller, L. L. V., De Groote, E., Bojsen‐Møller, K. N., Davey, J., Henríquez‐Olguin, C., Li, Z., Knudsen, J. R., Jensen, T. E., Madsbad, S., Gregorevic, P., Richter, E. A., & Sylow, L. (2019). Mechanisms involved in follistatin‐induced hypertrophy and increased insulin action in skeletal muscle. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.12474

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.